| http://www.w3.org/ns/prov#value | - Endo intends to use the net proceeds from the offering for general corporate purposes, which may include acquisitions, including the acquisition of DAVA Pharmaceuticals, Inc.Conference Call InformationEndo will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m.
|
